These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26075455)

  • 1. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A: Outcomes During One Complete Treatment Cycle.
    Osaki T; Osaki MH; Osaki TH; Hirai FE; Campos M
    Cornea; 2016 Feb; 35(2):220-5. PubMed ID: 26619386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
    Osaki T; Osaki MH; Osaki TH; Hirai FE; Nallasamy N; Campos M
    Br J Ophthalmol; 2016 Jul; 100(7):963-970. PubMed ID: 26541432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm.
    Moon NJ; Lee HI; Kim JC
    J Korean Med Sci; 2006 Feb; 21(1):131-5. PubMed ID: 16479079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
    Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
    Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does blepharospasm effect biometric parameters and intraocular lens power calculations?
    Basol I; Ilhan HD
    Int Ophthalmol; 2024 Aug; 44(1):358. PubMed ID: 39198275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
    Mali YP; Schultze RL; Wladis EJ
    Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
    Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
    Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
    JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
    Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
    Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
    Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.